Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:BLBD NASDAQ:CRSP NASDAQ:NTLA NASDAQ:NVDA NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$27.29+3.6%$31.39$15.60▼$38.26$2.71B2.182.67 million shs1.85 million shsBLBDBlue Bird$81.28-0.3%$73.61$42.89▼$83.39$2.58B1.35442,130 shs638,782 shsCRSPCRISPR Therapeutics$48.15+2.5%$52.86$44.12▼$78.48$4.53B1.711.71 million shs1.38 million shsNTLAIntellia Therapeutics$11.47+5.0%$14.17$7.95▼$28.25$1.53B1.774.67 million shs3.51 million shsNVDANVIDIA$207.29+2.0%$209.04$164.07▼$236.54$4.92T2.21131.31 million shs108.35 million shsVRTXVertex Pharmaceuticals$482.00+0.3%$464.12$362.50▼$533.67$121.95B0.291.86 million shs1.11 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+3.65%-11.65%-20.06%-13.88%+29.77%BLBDBlue Bird-0.27%+5.18%+9.85%+30.36%+89.51%CRSPCRISPR Therapeutics+2.47%-4.58%-10.98%-14.66%-26.30%NTLAIntellia Therapeutics+5.04%-13.76%-26.80%-30.78%-9.18%NVDANVIDIA+1.97%-2.13%-1.61%+2.37%+20.95%VRTXVertex Pharmaceuticals+0.31%+1.19%+6.72%+10.13%+5.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$27.29+3.6%$31.39$15.60▼$38.26$2.71B2.182.67 million shs1.85 million shsBLBDBlue Bird$81.28-0.3%$73.61$42.89▼$83.39$2.58B1.35442,130 shs638,782 shsCRSPCRISPR Therapeutics$48.15+2.5%$52.86$44.12▼$78.48$4.53B1.711.71 million shs1.38 million shsNTLAIntellia Therapeutics$11.47+5.0%$14.17$7.95▼$28.25$1.53B1.774.67 million shs3.51 million shsNVDANVIDIA$207.29+2.0%$209.04$164.07▼$236.54$4.92T2.21131.31 million shs108.35 million shsVRTXVertex Pharmaceuticals$482.00+0.3%$464.12$362.50▼$533.67$121.95B0.291.86 million shs1.11 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+3.65%-11.65%-20.06%-13.88%+29.77%BLBDBlue Bird-0.27%+5.18%+9.85%+30.36%+89.51%CRSPCRISPR Therapeutics+2.47%-4.58%-10.98%-14.66%-26.30%NTLAIntellia Therapeutics+5.04%-13.76%-26.80%-30.78%-9.18%NVDANVIDIA+1.97%-2.13%-1.61%+2.37%+20.95%VRTXVertex Pharmaceuticals+0.31%+1.19%+6.72%+10.13%+5.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.64Moderate Buy$46.8571.66% UpsideBLBDBlue Bird 2.78Moderate Buy$82.171.09% UpsideCRSPCRISPR Therapeutics 2.58Moderate Buy$67.7840.76% UpsideNTLAIntellia Therapeutics 2.30Hold$20.1976.00% UpsideNVDANVIDIA 2.98Moderate Buy$304.2646.78% UpsideVRTXVertex Pharmaceuticals 2.88Moderate Buy$559.6116.10% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026BLBDBlue Bird BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $85.007/17/2026BEAMBeam Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026NTLAIntellia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)7/15/2026NTLAIntellia Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradePeer Perform ➝ Underperform$9.007/14/2026NVDANVIDIA KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$310.00 ➝ $330.007/13/2026VRTXVertex Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$545.00 ➝ $585.007/13/2026VRTXVertex Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$542.00 ➝ $560.007/10/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $17.007/8/2026NVDANVIDIA Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$164.01M17.12N/AN/A$12.20 per share2.24BLBDBlue Bird$1.48B1.74$4.69 per share17.34$8.06 per share10.08CRSPCRISPR Therapeutics$3.51M1,323.10N/AN/A$20.17 per share2.39NTLAIntellia Therapeutics$67.67M23.68N/AN/A$5.80 per share1.98NVDANVIDIA$253.49B19.79$4.82 per share43.03$6.47 per share32.04VRTXVertex Pharmaceuticals$12.22B10.01$17.63 per share27.34$73.57 per share6.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)BLBDBlue Bird$127.72M$4.0719.9716.221.108.91%53.68%22.19%8/5/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)NVDANVIDIA$120.07B$6.5331.7417.100.4562.97%96.94%72.16%8/26/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8628.5925.602.0935.51%23.86%17.13%8/3/2026 (Estimated)Latest CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NTLAIntellia Therapeutics-$0.80N/AN/AN/A$12.98 millionN/A8/5/2026Q3 2026BLBDBlue Bird$1.22N/AN/AN/A$485.73 millionN/A8/4/2026Q2 2026BEAMBeam Therapeutics-$1.1064N/AN/AN/A$16.37 millionN/A8/3/2026Q2 2026CRSPCRISPR Therapeutics-$1.1993N/AN/AN/A$7.45 millionN/A8/3/2026Q2 2026VRTXVertex Pharmaceuticals$4.74N/AN/AN/A$3.23 billionN/A5/20/2026Q1 2027NVDANVIDIA$1.76$1.87+$0.11$2.39$78.42 billion$81.62 billion5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/6/2026Q2 2026BLBDBlue Bird$0.8770$1.00+$0.1230$0.90$335.23 million$352.64 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.903.30%N/AN/A N/ABLBDBlue BirdN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVDANVIDIA$1.000.48%+14.87%15.31%1 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2026NVDANVIDIAquarterly$0.250.46%6/4/20266/4/20266/26/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam Therapeutics0.0916.9916.99BLBDBlue Bird0.281.831.27CRSPCRISPR Therapeutics0.3217.9717.96NTLAIntellia TherapeuticsN/A6.106.10NVDANVIDIA0.043.442.85VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%BLBDBlue Bird93.59%CRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%NVDANVIDIA65.27%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%BLBDBlue Bird1.10%CRSPCRISPR Therapeutics5.20%NTLAIntellia Therapeutics3.50%NVDANVIDIA3.94%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableBLBDBlue Bird2,01231.65 million31.30 millionOptionableCRSPCRISPR Therapeutics46096.45 million91.43 millionOptionableNTLAIntellia Therapeutics600139.72 million134.83 millionOptionableNVDANVIDIA42,00024.20 billion23.25 billionOptionableVRTXVertex Pharmaceuticals6,400253.81 million253.30 millionOptionableCRSP, VRTX, NTLA, BEAM, BLBD, and NVDA HeadlinesRecent News About These CompaniesDanica Pension Livsforsikringsaktieselskab Takes $11.67 Million Position in Vertex Pharmaceuticals Incorporated $VRTX1 hour ago | marketbeat.comABN Amro Investment Solutions Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX1 hour ago | marketbeat.comAndra AP fonden Has $10.67 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX2 hours ago | marketbeat.comAmova Asset Management Americas Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX2 hours ago | marketbeat.comBiotech IPO Gains Crush AI Listings With Standout 55% ReturnJuly 21 at 12:46 PM | finance.yahoo.comA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating UpJuly 21 at 12:46 PM | finance.yahoo.comMeeder Asset Management Inc. Buys 2,799 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 21 at 5:43 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Sold by KBC Group NVJuly 21 at 5:28 AM | marketbeat.comDimensional Fund Advisors LP Buys 43,682 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 21 at 3:59 AM | marketbeat.comBaader Bank Aktiengesellschaft Sells 8,324 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 21 at 3:27 AM | marketbeat.comWhy Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market TodayJuly 20 at 7:56 PM | finance.yahoo.comWhy Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market TodayJuly 20 at 7:01 PM | zacks.comVertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2July 20 at 9:28 AM | finance.yahoo.comHow FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment StoryJuly 20 at 9:28 AM | finance.yahoo.comWCM Investment Management LLC Has $496.93 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 20 at 6:08 AM | marketbeat.comVertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth WatchingJuly 19 at 8:30 PM | fool.comVertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth WatchingJuly 19 at 7:45 PM | fool.comSEB Asset Management AB Invests $62.94 Million in Vertex Pharmaceuticals Incorporated $VRTXJuly 19 at 6:15 AM | marketbeat.comSwiss National Bank Has $332.49 Million Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 19 at 6:07 AM | marketbeat.comJennison Associates LLC Sells 509,482 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 19 at 5:35 AM | marketbeat.comAssetmark Inc. Has $26.77 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXJuly 19 at 3:12 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 AI Stocks That Could Benefit as AI Moves Beyond the Data CenterBy Thomas Hughes | July 5, 2026The AI Chip Sell-Off Looks Scary, But the Real Story May Be LiquidityBy Jeffrey Neal Johnson | July 7, 2026Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI StocksBy Thomas Hughes | June 30, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.By Ryan Hasson | June 23, 2026CRSP, VRTX, NTLA, BEAM, BLBD, and NVDA Company DescriptionsBeam Therapeutics NASDAQ:BEAM$27.29 +0.96 (+3.65%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$27.01 -0.28 (-1.03%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Blue Bird NASDAQ:BLBD$81.28 -0.22 (-0.27%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$80.08 -1.20 (-1.48%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Blue Bird Corporation, together with its subsidiaries, designs, engineers, manufactures, and sells school buses in the United States, Canada, and internationally. The company operates through two segments, Bus and Parts. It offers Type C, Type D, and specialty buses; and alternative power options through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses, as well as diesel engines. The company also sells replacement bus parts; and provides financing services and extended warranties related to its products. Blue Bird Corporation sells its products through drop ship and a network of dealers, as well as directly to fleet operators, the United States government, and state governments; independent service centers; and maintains a parts distribution center. Blue Bird Corporation was founded in 1927 and is headquartered in Macon, Georgia.CRISPR Therapeutics NASDAQ:CRSP$48.15 +1.16 (+2.47%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$48.24 +0.09 (+0.20%) As of 05:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$11.47 +0.55 (+5.04%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$11.52 +0.05 (+0.44%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.NVIDIA NASDAQ:NVDA$207.29 +4.01 (+1.97%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$205.42 -1.87 (-0.90%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.Vertex Pharmaceuticals NASDAQ:VRTX$482.00 +1.50 (+0.31%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$480.22 -1.78 (-0.37%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
